Sarepta Therapeutics, Inc.’s gene therapy setback in Duchenne muscular dystrophy (DMD) could be Pfizer Inc.s gain. One day after Sarepta announced that the Phase III confirmatory trial testing Elevidys (delandistrogene moxeparvovec-rokl) in DMD failed to meet the primary endpoint, Pfizer said it remains hopeful that its DMD gene therapy, fordadistrogene movaparvovec, could yield stronger Phase III data.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?